USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
PARION SCIENCES, INC.
Address:
2525 MERIDIAN PKY, STE 260
DURHAM, NC 27713-2261
Phone:
N/A
URL:
N/A
EIN:
156219348
DUNS:
96851774
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,577,573.00 5
SBIR Phase II $3,931,986.00 4

Award List:

PHARMACOTHERAPY FOR XEROSTOMIA IN SJOGREN'S SYNDROME

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$489,999.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Sjogren's syndrome (SS) is a slowly progressive inflammatory disorder characterized by lymphocyte-mediated destruction ofOverall, this application was found to have significant and substantial scientific merit, and is recommended with an exc exocrine glands and… More

DEVELOPMENT OF EPITHELIAL SODIUM CHANNEL BLOCKERS FOR CF

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$364,501.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Our preliminary data support the hypothesis that 552-02 is a potent, selective inhibitor of epithelial sodium channels that is effective in enhancing mucociliary clearance and is well tolerated when administered as a single dose by inhalation aerosol in normal… More

DEVELOPMENT OF EPITHELIAL SODIUM CHANNEL BLOCKERS FOR CF

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$983,544.00
Agency:
HHS
Principal Investigator:
Judith A. Stgeorge
Abstract:
DESCRIPTION (provided by applicant): Our preliminary data support the hypothesis that 552-02 is a potent, selective inhibitor of epithelial sodium channels that is effective in enhancing mucociliary clearance and is well tolerated when administered as a single dose by inhalation aerosol in normal… More

PHARMACOTHERAPRY FOR XEROSTOMIA IN SJOGREN'S SYNDROME

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$379,296.00
Agency:
HHS
Principal Investigator:
Karl Donn
Abstract:
DESCRIPTION (provided by applicant): Sjogren's syndrome (SS) is a slowly progressive inflammatory disease characterized by lymphocyte- mediated destruction of exocrine glands and internal organ involvement due to autoantibody production or pre- existing co nnective tissue disorder. Over time,… More

The Development Epithelial Sodium Channel Blockers for Chronic Dry Eye

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$159,264.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Dry eye is one of the most frequently diagnosed ocular diseases affecting more than 5 million people in the United States alone. Dry eye is s a multi-factorial disease, resulting from a common etiology of insufficient t ear film causing ocular surface damage and… More

Hypertonic Saline for Cystic Fibrosis

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$244,797.00
Agency:
HHS
Principal Investigator:
Benjamin Yerxa – 919-941-9777
Abstract:
DESCRIPTION (provided by applicant): Cystic fibrosis (CF) is an autosomal lethal disease characterized that affects ~30,000 individuals in the US. CF lung disease, the major cause of mortality in CF, is caused by dehydration of airway secretions that leads to mucous adhesion, infection and airways… More

The Development Epithelial Sodium Channel Blockers for Chronic Dry Eye

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$1,059,726.00
Agency:
HHS
Principal Investigator:
Karl H. Donn – 919-313-1185
Abstract:
DESCRIPTION (provided by applicant): Dry eye is one of the most frequently diagnosed ocular diseases affecting more than 5 million people in the United States alone. Dry eye is s a multi-factorial disease, resulting from a common etiology of insufficient tear film causing ocular surface damage and… More

Novel Mucolytic Agents

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$319,012.00
Agency:
HHS
Principal Investigator:
Bill Thelin – 919-313-1199
Abstract:
DESCRIPTION (provided by applicant): Mucus transport is the fundamental defense of the airways against inhaled particulates/infectious agents. Abnormalities in the mucus transport system characterize a complex of muco-obstructive airway diseases, such as cystic fibrosis (CF) and chronic bronchitis… More

Hypertonic Saline for Cystic Fibrosis

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$1,509,420.00
Agency:
HHS
Principal Investigator:
Bill Thelin – 919-313-1199
Abstract:
DESCRIPTION (provided by applicant): Cystic fibrosis (CF) is an autosomal lethal disease characterized that affects ~30,000 individuals in the US. CF lung disease, the major cause of mortality in CF, is caused by dehydration of airway secretions that leads to mucous adhesion, infection and airways… More